Karyopharm Therapeutics

Selinexor (XPOVIO, KCP-330-004) is an oral small-molecule antineoplastic agent developed by Karyopharm Therapeutics Inc. The program evaluated selinexor in glioblastoma as a Phase 2 indication but was terminated as of January 26, 2023. Despite the glioblastoma program's discontinuation, selinexor has achieved regulatory approval in multiple markets: the United States (NDA212306), European Union (EMEA/H/C/005127, authorized August 14, 2023 under the brand name Nexpovio), and Australia (TGA listing September 1, 2022 under Antengene distribution). The drug is administered orally and classified as an antineoplastic and immunomodulating agent (L01 therapeutic class). Karyopharm's strategy has focused on approved indications outside glioblastoma, with marketing authorization holders including Stemline Therapeutics B.V. in the EU and Antengene in Australia. The termination of the glioblastoma Phase 2 program reflects a strategic pivot away from this indication, though the approved formulation continues to be marketed in other oncology settings.

Glioblastoma represents one of the most aggressive primary brain tumors with poor prognosis and limited treatment options, creating a significant unmet medical need. The termination of the selinexor glioblastoma program suggests that Phase 2 efficacy or safety data did not support advancement to Phase 3 trials, or that Karyopharm prioritized development resources toward indications with stronger clinical signals. The competitive landscape for glioblastoma includes approved therapies such as temozolomide-based regimens and bevacizumab, though novel mechanisms remain sought. Selinexor's approved status in other oncology indications demonstrates clinical utility in select malignancies, but the glioblastoma indication did not advance to regulatory approval. The market relevance of the glioblastoma program termination reflects the high failure rate of CNS-penetrant oncology agents and the challenges of demonstrating efficacy in this difficult-to-treat disease. Patient populations with glioblastoma remain underserved, but the discontinuation of this program removes selinexor as a potential therapeutic option for this indication. Commercial significance is limited to approved non-glioblastoma indications, where selinexor has established a market presence in multiple geographies.

Drug Class: Antineoplastic and immunomodulating agent (ATC L01)

Modality: Small-molecule oral therapeutic

Route of Administration: Oral

Mechanism of Action: Not disclosed in available facts

Target: Not disclosed in available facts

Brand Names: XPOVIO (approved formulation), Nexpovio (EU approved name)

Related Therapies: Selinexor is approved in multiple oncology indications across US, EU, and Australia markets, indicating established clinical utility in select malignancies outside glioblastoma.

First Approval: United States approval documented (NDA212306); European Union approval August 14, 2023; Australian approval September 1, 2022

Patent Status: Not disclosed in available facts

United States: Selinexor approved via NDA212306; sponsor listed as Karyopharm Therapeutics

European Union: Approved August 14, 2023 under brand name Nexpovio (EMEA/H/C/005127); Marketing Authorization Holder: Stemline Therapeutics B.V.

Australia: Listed on ARTG September 1, 2022; PBS codes assigned (13085Q, 13086R, 13099K, 13103P, 13104Q, 13105R); Sponsor: Antengene (AUS) Pty. Ltd.

China: Clinical trials ongoing (NCT04562870, NCT06449482); regulatory status remains in clinical trial phase

Japan (PMDA): Regulatory status not yet disclosed in available facts

Glioblastoma Indication: Phase 2 program (NCT01986348) terminated January 26, 2023; no regulatory approval achieved for this indication

Strategic Implications: The termination of selinexor's glioblastoma Phase 2 program reflects Karyopharm's strategic reallocation of resources toward indications with stronger clinical evidence and regulatory approval pathways. The company has successfully achieved approvals in multiple geographies for other oncology indications, suggesting that glioblastoma did not meet internal efficacy or commercial thresholds.

Competitive Implications: The discontinuation removes selinexor as a potential therapeutic option for glioblastoma patients, leaving the competitive landscape unchanged. Existing approved therapies and agents in development from competitors remain the primary options for this indication.

Clinical Development Catalysts: No further development expected in glioblastoma. Future catalysts are limited to label expansions or new indications for the approved selinexor formulation in non-CNS malignancies.

Expected Milestones: No additional milestones anticipated for the glioblastoma program. Monitoring should focus on selinexor's commercial performance in approved indications and potential regulatory actions in other geographies (e.g., Japan PMDA).